ImmunityBio's Cancer Treatment Wins European Nod, Shares Jump on Approval

The stock market rewarded ImmunityBio’s latest regulatory win handsomely. Shares of the biotech company jumped 41.9% following news that the European Commission has granted conditional marketing authorization for Anktiva (nogapendekin alfa inbakicept), a new immunotherapy designed to combat a challenging form of bladder cancer. This approval marks a significant milestone for the company, which has now established a global presence across 33 countries in just under two years since its initial FDA approval in 2024.

What Triggered the 41.9% Stock Surge?

The catalyst was straightforward: Europe’s green light for a cancer combination therapy that addresses a genuine treatment gap. Anktiva, administered alongside Bacillus Calmette-Guérin (BCG), is now the first immunotherapy authorized in Europe specifically for patients with BCG-unresponsive bladder cancer—essentially, cases where the standard first-line treatment has failed. This approval applies to adult patients with non-muscle invasive bladder cancer that has progressed to carcinoma in situ stage, with or without papillary tumors.

The European Medicines Agency’s advisory committee had previously recommended the authorization, paving the way for the European Commission’s conditional approval. This pathway allows regulators to approve treatments addressing unmet medical needs earlier, provided the benefits outweigh risks and companies commit to submitting long-term follow-up data. ImmunityBio must continue monitoring study participants and provide updated safety and efficacy information to the EMA, with the authorization subject to annual renewal.

Anktiva Plus BCG: A Breakthrough Cancer Combination

Why is this particular combination drawing regulatory attention? The approval is anchored in solid clinical evidence. The phase II/III QUILT-3.032 trial enrolled 100 adults with the specific type of cancer targeted by this therapy. Participants received intravesical Anktiva alongside BCG treatment, and the results were compelling.

The trial demonstrated a 71% complete response rate—meaning nearly three-quarters of patients achieved full tumor elimination. Some of these responses persisted for more than 54 months and remained ongoing at the study’s completion. Among patients who initially responded, 66% maintained complete response at 12 months, with 42% still showing complete response at the 24-month mark. The median duration of complete response reached six months.

Beyond tumor control, the study tracked survival metrics crucial for cancer patients. Cystectomy-free survival—a key measure avoiding the need for bladder removal surgery—reached 96% at 12 months, 90% at 24 months, and 84% at 36 months. Disease-specific survival exceeded 99% at both 24 and 36 months, suggesting the treatment not only controlled cancer progression but also extended overall survival.

Safety Profile: Mostly Manageable Side Effects

The cancer therapy’s side effect profile weighed favorably in the regulatory decision. Pooled safety data from the trial showed that most treatment-related adverse events were mild to moderate. The most commonly reported reactions included dysuria (painful urination), hematuria (blood in urine), urinary frequency, urinary tract infections, urinary urgency, fatigue, chills, musculoskeletal pain, and fever. No unexpected safety signals emerged that would contraindicate the treatment.

Why Europe Gets This Cancer Drug First

There’s an interesting asymmetry between European and American markets worth noting. Bladder cancer ranks among Europe’s most common cancers, with roughly three-quarters of diagnoses representing the non-muscle invasive form—the type addressed by this approval. For the subset of patients whose disease doesn’t respond to BCG, options have been severely limited, with radical cystectomy (surgical bladder removal) often presented as the primary alternative despite its profound impact on quality of life and unsuitability for certain patient populations.

Europe holds a strategic advantage in making this cancer therapy widely available: the continent supports broader BCG supply chains with approximately six approved BCG strains in clinical use, compared to just one approved strain in the United States. This supply advantage helps sustain combination treatment approaches and reduces the bottlenecks affecting American markets. Meanwhile, ImmunityBio is actively working to navigate ongoing BCG shortages in the U.S., which could determine how quickly the approved cancer therapy gains market penetration domestically.

How IBRX Stacks Up Against Competitors

ImmunityBio carries a Zacks Rank #2 (Buy) rating, positioning it among favorably viewed biotech plays, though not in the top tier. For comparison, three other biotech stocks command higher Zacks ratings. Harmony Biosciences (HRMY), Alkermes (ALKS), and Castle Biosciences (CSTL) each sport a Zacks Rank #1 (Strong Buy).

Harmony Biosciences’ 2026 earnings estimates have risen from $3.72 to $4.00 per share over the past 60 days, though HRMY shares have declined 3.7% over the past six months. The company beat earnings estimates in two of the last four quarters. Alkermes shows a different trajectory: 2026 EPS estimates climbed from $1.54 to $1.91 within 60 days, and ALKS shares gained 10.5% over six months, with earnings beating estimates in three of the trailing four quarters. Castle Biosciences demonstrated the strongest momentum, with 2026 loss estimates narrowing from $1.06 to 96 cents per share, and CSTL surging 70.2% over six months, beating earnings expectations in three of four recent quarters.

The Broader Biotech Landscape and Cancer Research Pipeline

The regulatory environment for cancer therapies continues evolving. Ongoing regulatory expansion across EU markets is expected to shift strategic focus toward pricing, reimbursement, and patient access questions—the practical implementation challenges beyond the approval stage. This approval for ImmunityBio’s cancer combination represents one piece of a broader biotech landscape where companies compete on clinical efficacy, regulatory positioning, and commercial execution.